Opportunity assessment: high. Science Corporation has implanted its PRIMA vision chip in its first patient with Stargardt disease, an inherited condition that slowly destroys central vision and has no cure. CEO Max Hodak announced the news onstage at TechCrunch Disrupt, according to TechCrunch AI. Hodak co-founded Neuralink and served as its president. The surgery took place in May as part of an ongoing trial at the Sydney Eye Hospital in Australia.
The early results are encouraging. In his first rehabilitation session, the patient saw a letter. In his second, he read a word.
🎯 Situation Report
Here’s what’s on the ground right now:
- PRIMA is already on sale in Europe. It’s approved for patients who lost their sight to geographic atrophy, an advanced form of age-related macular degeneration.
- Stargardt disease is the new target. About 150,000 people worldwide have lost vision to it. It kills the eye’s light-sensing cells in the outer retina but can leave the inner retina working. That’s the layer that passes visual signals on to the brain.
- The procedure takes about an hour. Surgeons place a small chip at the back of the eye, where the photoreceptors have died.
- Camera glasses do the seeing. The patient wears glasses with a built-in camera that send a view of the world to the chip. The implant then acts as a set of artificial photoreceptors.
Hodak boiled the idea down to something simple:
“vision is electrical potential, like electrical activity down the optic nerve. That’s all vision is to the brain, and so if you can get the optic nerve to signal the rest of the brain correctly, then you can provide vision to it.”
🔍 Current Limits
Don’t picture full sight coming back. The current implant measures two millimeters by two millimeters. Hodak said using it is “like looking through a straw.”
Patients get a black-and-white patch in the middle of their vision. Still, Hodak called it “high-contrast sharp,” and it’s sharp enough to make out a couple of letters at a time.
To widen the field of view, the team has two engineering problems to solve:
- Curvature. A bigger implant has to follow the curve of the eye.
- Electrode size. Smaller electrodes are needed to get close to natural levels of detail.
Hodak says the next-generation device should be in humans within the next year. He thinks the company can get “pretty close to native acuity” within five years.
🧠 Strategic Picture
This matters for more than eye care. Hodak is quietly redrawing what counts as a brain-computer interface (BCI).
“The retina is part of the central nervous system,” he said. “We consider cochlear implants, retinal prostheses, motor prostheses, these are all different types of BCIs.”
What stands out here is the business logic. Most BCI coverage is about people moving a cursor with their thoughts. Science Corporation is taking a slower route. It’s proving its methods work and building a revenue-generating medical product first. That’s a smart hedge in a field where funding can run dry before the science pays off.
The company’s brain implant also differs from Neuralink’s on design:
- Science Corp: a sensor that sits inside the skull, resting on top of the brain.
- Neuralink: a device inserted directly into brain tissue.
📡 What Comes Next
Hodak gave a few hints about the roadmap:
- The first brain indication is a neurodegenerative disease “that everybody’s heard of.” It hasn’t been named publicly yet.
- Stroke is on the list. The idea is to connect two deep-brain areas so the device could stand in for tissue lost to stroke. Hodak said that’s not possible with conventional electrodes.
- The long-term goal is ambitious. He described it as understanding “how the brain creates the mind” and learning “to build engineered brains.”
Hodak also made a bold prediction. Science Corporation isn’t designing for “healthy 40-year-olds,” he said, but it believes most people will need some kind of BCI by age 60 or 70. “We want to figure out how do we extend not just lifespan but health span,” he said.
⚡ Bottom-Line Assessment
For people working in AI and neurotech, the takeaway is clear. BCIs are moving from a sci-fi interface into a family of medical devices. Vision restoration is the beachhead. If next year’s larger implant delivers, expect more pressure on Neuralink and its rivals to show real clinical results, not just demos.
The next checkpoint is the next-gen implant reaching human trials, which Hodak expects within a year. Full details are available in TechCrunch AI’s original report.